Whether it’s a bull or bear market, TrendingWallStreet has you covered. Take a few minutes to register with us at http://www.bulltrends.com/ to get full access to our free stock reports.
Get more information on InterMune Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/ITMN
Get more information on ENDEXX Corp. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/EDXC
Gilead Sciences Inc. (NASDAQ: GILD) shares closed up a modest 2.83 percent on Monday with nearly 10.5 million shares traded. The stock was one of the most active stocks in the NASDAQ. The company announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults.
Get more information on Gilead Sciences Inc. and free access to the in-depth equity report at: www.TrendingWallStreet.com/stockquote/GILD
Disclosure: TrendingWallStreet.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please read our report and visit our website, for complete risks and disclosures.